Literature DB >> 2878741

Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties.

J B Kostis, R C Rosen.   

Abstract

Among the side effects commonly reported with the use of beta-blockers are symptoms related to the central nervous system (CNS). In this study we compared the effects of four beta-blockers with different ancillary properties (atenolol, metoprolol, propranolol, and pindolol) and placebo on objective and subjective measures of CNS function in 30 healthy male subjects. All subjects were randomly assigned to a double-blind, placebo controlled, Latin-square design study in which five 1 week periods of drug or placebo administration were separated by 2 week washout periods. Laboratory evaluations were conducted at the end of each treatment period, and included multistage exercise stress testing; questionnaire assessments of mood state, sexual function, and sleep habits; tests of psychomotor function; and overnight polysomnographic measures of sleep. Significant effects on sleep continuity were observed for each of the lipophilic drugs, as reflected in the number of awakenings (pindolol = 6.4 +/- 5.0; propranolol = 6.3 +/- 3.2; metoprolol = 7.2 +/- 4.7; atenolol = 3.6 +/- 2.9; placebo = 3.9 +/- 2.7) and time of wakefulness (pindolol = 20.6 +/- 27.0 min; propranolol = 15.5 +/- 23.0 min; metoprolol = 19.5 +/- 24.3 min; atenolol = 10.2 +/- 11.6 min; placebo = 9.2 +/- 74.5 min). Only pindolol significantly affected rapid eye movement (REM) sleep time (pindolol = 54.5 +/- 21.9 min; placebo = 74.5 +/- 74.5 min) and REM latency (pindolol = 175.0 +/- 60.7 min; placebo = 95.4 +/- 43.8 min). Subjective reports of sleep similarly indicated increased wakefulness and greater restlessness with lipophilic beta-blockers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2878741     DOI: 10.1161/01.cir.75.1.204

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Measurement of the quality of life in clinical trials: in pursuit of the unapproachable?

Authors:  L Offerhaus
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia.

Authors:  Yuji Kadoi; Shigeru Saito
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

Review 4.  Drugs and sport. Research findings and limitations.

Authors:  P M Clarkson; H S Thompson
Journal:  Sports Med       Date:  1997-12       Impact factor: 11.136

5.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

6.  Portable Sleep Monitoring Systems: Broadening the Horizons.

Authors:  Naima Covassin; Virend K Somers
Journal:  J Clin Sleep Med       Date:  2017-06-15       Impact factor: 4.062

7.  Beta-blocker effects on sexual function in normal males.

Authors:  R C Rosen; J B Kostis; A W Jekelis
Journal:  Arch Sex Behav       Date:  1988-06

8.  Habitual sleep duration associated with self-reported and objectively determined cardiometabolic risk factors.

Authors:  Michael A Grandner; Subhajit Chakravorty; Michael L Perlis; Linden Oliver; Indira Gurubhagavatula
Journal:  Sleep Med       Date:  2013-10-28       Impact factor: 3.492

9.  Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.

Authors:  T Kaila; R Marttila
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

10.  CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

Authors:  A L van Steveninck; M S Pieters; H C Schoemaker; D D Breimer; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.